Abstract 104: Cost-Effectiveness of Edoxaban vs. Rivaroxaban for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation (NVAF) in the US [Session Title: Poster Session I]

Conclusions: These results showed that once-daily edoxaban (60mg/30mg dose-reduced) regimen is a highly cost-effective treatment relative to rivaroxaban (20mg/15mg dose-reduced) for stroke prevention in NVAF patients.

Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Miller, J. D., Ye, X., Lenhart, G. M., Farr, A. M., Tran, O. V., Kwong, W. J., Magnuson, E., Weintraub, W. Tags: Session Title: Poster Session I Source Type: research